OTCPicks.com Stocks to Watch for Thursday, March 15th

Recommended Stock Newsletters
#1. PennyStockWarfare
#2. Nova Stocks
#3. Penny Stock Finder

OTCPicks Publisher Newsletter

OTCPicks.com Stocks to Watch for Thursday, March 15th ECYT, ECDC, NEOM, HMNY, SAVW, MDFI Our Stocks to Watch tomorrow include Endocyte Inc. (NASDAQ: ECYT), East Coast Diversified Corp. (OTCBB: ECDC), NeoMedia Technologies Inc. (OTCBB:

NEOM), Helios & Matheson Information Technology Inc. (NASDAQ: HMNY), SavWatt USA Inc. (OTCBB: SAVW) and MedeFile International Inc. (OTC:

MDFI).Visit http://otcpicknews.com/emailmarketer/link.phpM940&N75&L1&F=T to register for our Stocks to Watch Newsletter and Email Stock Watch Alerts.ENDOCYTE INCORPORATED (NASDAQ: ECYT) “Up 58.33% on Wednesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N75&L41&F=T Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company`s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.ECYT News:MARCH 13 – Endocyte to Submit EU Conditional Marketing Authorization Applications for EC145 and EC20– Expects to File Third Quarter of 2012 – EC145 and EC20 Granted Orphan Drug Status by European Commission – Updated Overall Survival Data Improved Compared to Interim AnalysisEndocyte, Inc. (NASDAQ: ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced that, per discussions with EU health authorities, the Company will submit EU conditional marketing authorization applications (MAA) for EC145 and EC20 for treatment of patients with folate-receptor positive platinum resistant ovarian cancer.

The therapeutic, EC145, and the diagnostic imaging agent, EC20, have also both been granted orphan drug status by the European Commission.”After discussions with EU health authorities about Phase 3 trial plans and updated clinical data, including an updated overall survival analysis, we are pleased to move forward with these applications,” said Ron Ellis, Endocyte`s president and chief executive officer. “Targeting patients with a high unmet medical need is a prerequisite to pursuing this regulatory path and, by any measure, these patients fit that definition.”Endocyte plans to file two marketing authorization applications, one application for EC145 and another for EC20, in the third quarter of 2012.

This will ensure that the Phase 3 PROCEED trial enrollment is well underway. Per agreement with the EU regulators, if conditional marketing authorization is granted, data from the PROCEED trial would be submitted following authorization and PROCEED would serve as the confirmatory trial to support conversion to regular marketing authorization for EC145 and EC20.The marketing authorization applications will be supported by four clinical studies: a Phase 1 study in solid tumors, two single-agent, single-arm Phase 2 studies in ovarian cancer and non small cell lung cancer, and the PRECEDENT trial, a randomized study in platinum-resistant ovarian cancer. The results of the PRECEDENT trial demonstrated a statistically significant delay in disease progression or death in the overall population, with the largest improvement observed in the FR(++) patient population, those with all tumors positive for the folate receptor.

Women with FR(++) platinum resistant ovarian cancer who received EC145-based therapy experienced a 62 percent decrease in their risk of progression [HR 0.381, p= 0.018] compared to women receiving chemotherapy alone. Median progression free survival (PFS; the time without disease progressing) in the EC145 based treatment arm was 5.5 months compared to 1.5 months of women who received chemotherapy alone. Tumor shrinkage (overall response rate) was observed in 17.3 percent of women receiving the EC145-based therapy compared to 6.7 percent in patients treated with chemotherapy alone.In addition, Endocyte today announced updated overall survival data from the PRECEDENT trial, which show improvement compared to the results announced in December 2011. Overall survival was a secondary endpoint in the PRECEDENT trial, but it was underpowered to demonstrate a definitive result in this endpoint. In particular, the overall survival hazard ratio for the FR(++) patient group was 1.097. Adjusting for prognostic imbalances between the study arms, the adjusted hazard ratio of 0.481 reflects a 52 percent reduction in the risk of death. Overall survival statistics in the intent-to-treat population were also slightly improved compared to those announced in December and those data will be presented at an upcoming medical conference.”Patients with platinum-resistant ovarian cancer represent a high unmet medical need, and the presence of the folate receptor is associated with more rapid disease progression and shorter life expectancy,” said Ignace B.

Vergote, M.D., Ph.D., from University Hospital Leuven, in Belgium. “Because EC145 targets the folate receptor, these patients also have the potential to receive the greatest improvement over standard therapy. Being able to use EC20 to select patients who will most likely respond to the treatment will benefit both patients and doctors and is an important step towards implementing personalized medicine.”ABOUT EC145EC145 is a conjugate of the vitamin folate and a super-potent vinca alkaloid. Folate is required for cell division and rapidly dividing cancer cells often over-express folate receptors in order to capture enough folate to support cell division. By attaching a chemotherapy drug to folate through proprietary chemistry, EC145 targets cancer cells while avoiding most normal cells. This targeted approach is designed to provide treatment with super-potent drugs while lowering toxicity compared to standard chemotherapy.ABOUT EC20EC20 is a folate-targeted molecular imaging agent that is being developed as a non-invasive method to identify tumors that over-express folate receptors. These tumors are the molecular target of Endocyte`s folate-targeted therapeutic compounds such as EC145. To date, EC20 has been administered to over 500 patients.ABOUT ORPHAN DRUG DESIGNATIONEMA`s Orphan Medicinal Product Designation is designed to promote the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. This designation will provide ten years of marketing exclusivity if the product candidate is approved for marketing for the designated orphan indication in the European Union. It also provides special incentives for sponsors, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of application for marketing approval.EAST COAST DIVERSIFIED CORPORATION (OTCBB: ECDC) “Up 52.63% on Wednesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N75&L12&F=T East Coast Diversified Corp. operates through its subsidiary, EarthSearch Communications, Inc. East Coast Diversified Corp. offers a portfolio of GPS devices, RFID interrogators, integrated GPS/RFID technologies and Tag designs. The company was founded in 2010 and is based in Atlanta, Georgia..

ECDC News:March 8 – EarthSearch Executes $1 Million Master Distributor Agreement with Asonics Live Interlink LTD KenyaEast Coast Diversified Corporation (OTCBB: ECDC), through its subsidiary EarthSearch Communications, Inc., announces the execution of Master Distributor agreement with Asonics Live Interlink Kenya for $350,000 in equipment and services purchased each year under the three year licensing agreement.The agreement would allow Asonics to be our exclusive representative in Kenya. Other partners in the market will now source products and support locally from Asonics which will be able to secure its own local distributors and partners to offer a variety of logistics solution provided by EarthSearch. EarthSearch technology provides complex logistics solution through its LogiBoxx device, the GATIS platform for monitoring fixed assets and cargo in transit. Solutions provided by EarthSearch includes Oil Tanker monitoring, Workforce management, Tool tracking, Electronic locks for cargo, Warehouse management and access control solutions using EarthSearch proprietary wireless communication between GPS and RFID.”We have been working to establish strong presence in this region for some time now. It is a vibrant and fast growing market with significant need for cargo and asset security using advanced logistics application. I am looking forward to working with Thaddeus, Joyce and Jeff and all the other executives at Asonics,” said Kayode Aladesuyi, CEO of ECDCAsonics has been testing and piloting the EarthSearch LogiBoxx device and RFID solutions over the last several months and recently committed to become a master distributor with minimum annual commitment allocated for the Kenya market. Asonics will also be able to sell on a non exclusive basis to other markets in the region.”There is a significant need for EarthSearch technology and the solutions it provides in our country as well as in other markets in the region, the movement of cargo between countries in east Africa is now more vital than ever before. The recent launching of the Lamu port by Kenyan government which will link it with Ethiopia and Sudan in the effort to harness trade among African countries is a testament to the need for this solution,” said Mr Thaddeus Mailumunguti, CEO Asonics Live Interlink.NEOMEDIA TECHNOLOGIES INCORPORATED (OTCBB: NEOM) “Up 35.64% on Wednesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N75&L7&F=T NeoMedia Technologies, Inc. is the global leader in mobile barcode scanning solutions. The company`s technology allows mobile devices with cameras to read 1D and 2D barcodes and provide “one click” access to mobile content. Combining this technology with advanced analytics and reporting capabilities revolutionizes the way advertisers market to mobile consumers. NeoMedia provides the infrastructure to make 2D camera barcode scanning and its associated commerce easy, universal, and reliable — worldwide.NEOM News:March 8 – NeoMedia Launches Upgraded NeoReaderLeading barcode scanning application now updated with direct consumption features and other improvements on all platformsNeoMedia Technologies, Inc. (OTCBB: NEOM), the pioneer in global mobile barcode management solutions, today announced the launch of the updated NeoReader® barcode-scanning software applications for Apple iOS, Android, BlackBerry, Symbian and Windows Phone 7 users. The upgraded apps are available now from the Apple App Store™, Android MarketTM / Google PlayTM, BlackBerry App World™, Nokia Store and Windows® Marketplace for users to transform their devices into barcode scanners and seamlessly connect to mobile content.NeoReader bridges the gap between traditional and digital media, allowing all users with camera phones to scan both 2D and 1D code types in order to access specific web content, real-time product or service information, download content, or complete a mobile commerce transaction with one click.

Users no longer need to type in long URLs, scroll through long lists of search results or navigate cumbersome mobile phone menus.Some of the new features that will enable users to enjoy the value and convenience of a rich and relevant interactive experience, wherever they encounter a mobile barcode, are:* Ability to send email, SMS and make phone calls directly by scanning appropriate codes * Redesigned user interfaces for simpler and improved navigation * Optimized graphics performance in viewfinder mode as well as enhanced autofocus and snapshot support * Faster 1D and 2D barcode scanning * New ‘copy to clipboard’ functionality for scanned codesConsumers can easily download the NeoReader software to their phone by going to get.neoreader.com on their mobile browser or accessing their appropriate app store. HELIOS & MATHESON INFORMATION TECHNOLOGY (NASDAQ: HMNY) “Up 62.46% on Wednesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N75&L27&F=T Helios and Matheson Information Technology Inc. provides information technology services and solutions to various companies and organizations.

It offers application value management, application development, integration, independent validation, infrastructure, and information management services to banking, financial services, insurance, pharmaceutical, and manufacturing/automotive industries. The company was formerly known as Helios and Matheson North America Inc. and changed its name to Helios and Matheson Information Technology Inc. on May 2, 2011.

Helios and Matheson Information Technology Inc. was founded in 1982 and is headquartered in New York, New York. HMNY News:March 12 – Helios and Matheson Renews Contract With Pharma Major; Celebrates a 20-Year RelationshipHelios and Matheson Information Technology Inc. (NASDAQ: HMNY) (the “Company”), a 30 year old IT services organization focused on banking, financial services, insurance and healthcare sectors, has renewed its Master Services Agreement for a further period of 2 years with a pharmaceutical and healthcare giant. This agreement facilitates continued provision of project services to this Fortune 100 Company who has been a client of Helios and Matheson for over 20 years.SAVWATT USA INCORPORATED (OTCBB: SAVW) “Up 100.00% on Wednesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N75&L92&F=T Fast becoming the market leader in LED lighting, SavWatt focuses on developing innovative, energy-efficient and cost-effective LED lighting solutions. By delivering value added, application-specific LED lighting systems, we can significantly reduce energy costs and minimize our carbon footprint world-wide. SavWatt is leading the LED lighting revolution and setting the stage to obsolete the incandescent light bulb. SavWatt`s product families include LED fixtures, bulbs, street lights, and parking lights. SAVW News:No recent news for SavWatt USA, Inc. (OTCBB: SAVW).MEDEFILE INTERNATIONAL INCORPORATED (OTCBB: MDFI) “Up 14.29% on Wednesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N75&L6&F=T Headquartered in South Florida, MedeFile has developed and globally markets a proprietary, patient-centric, iPHR (Internet-enabled Personal Health Record) system for gathering, digitizing and organizing medical records so that individuals can have a comprehensive record of all of their medical visits. MedeFile`s primary product is its web-based MedeFile solution, a highly secure system for gathering, maintaining, accessing and sharing personal medical records. Interoperable with most electronic medical record management systems marketed to the healthcare industry, the MedeFile solution is designed to gather all of its members` actual medical records and create a single, comprehensive Electronic Health Record (EHR) that is accessible 24 hours a day, seven days a week by the member and the member`s authorized users on any web-enabled device (PC, cell phone, smartphone, e-reader) and portable MedeDrive unit. MDFI News:March 14 – MedeFile Set to Launch Pilot With National Long-Term Acute Care Hospital CompanyUpon Successful Pilot Completion, Promise Healthcare Will Look to Make MedeFile Personal Health Record the Cornerstone of Its Employee Health Management StrategyMedeFile International, Inc. (OTC: MDFI), a leader in Internet-enabled Personal Health Record (iPHR) management solutions, and Promise Healthcare, Inc., a leading national long-term acute care (LTAC) hospital company, today jointly announced that the Companies have agreed to implement a 90-day pilot program to test and confirm the ease of use, functionality and cost benefits derived from adopting MedeFile`s premium iPHR as an integral part of its employees` benefits package.Kevin Hauser, Chairman, President and CEO of MedeFile, stated, “For the past year, MedeFile`s market penetration strategy has largely focused on pursuing large wholesale contracts with leading healthcare institutions, insurance companies, large self-insured employer groups, trade unions and affinity groups. Consequently, we are thrilled to have won this opportunity with Promise, and view it as a major milestone that is expected to pave the way for conducting similar MedeFile programs with other major companies and organizations with which we are in active discussions. For all intent and purposes, we believe MedeFile has reached a very critical inflexion point in our Company`s evolution and we couldn`t be more excited about our future growth prospects.”The pilot with Promise will entail MedeFile enrolling each member of Promise`s corporate office staff on the MedeFile iPHR system. Upon successful completion of the 90-day pilot program, we anticipate Promise subsequently integrating MedeFile`s premium iPHR into its employee benefits package afforded to each of its approximate 2900 eligible employees. In addition, employees` family members will also be entitled to enroll as MedeFile subscribers at a pre-negotiated discounted rate.Commenting on the decision to move forward with MedeFile, Peter Baronoff, Chairman and Chief Executive Officer of Promise Healthcare, noted, “Promise has earned distinction as a national healthcare organization that makes `people` our highest priority. Because we understand and appreciate the significant value of our employees and the important roles they play in delivering superior care to our patients, we strive every day to be an excellent, people-oriented, healthcare employer. If the pilot proves as successful as we expect it will, we look forward to making MedeFile the cornerstone of our employee health management strategy.”Representing a highly innovative, yet hassle-free and easy-to-use approach to portable, personal health records management, MedeFile combines advanced digital technology and the Internet to make medical data instantly accessible to each MedeFile member and his or her authorized healthcare providers from anywhere in the world. Upon being enrolled on the MedeFile system as a Premium subscriber, the MedeFile team goes to work contacting all of the member`s present and previous care providers (including primary physicians, medical specialists and even dentists) to collect, digitize, index and store all actual medical and dental records and files, including actual EKGs, x-rays, MRIs, physician notes, lab results, etc. In addition, each member may also store copies of living wills, healthcare durable powers of attorney, parental authorizations to treat a minor, organ donor forms and other critical documents.OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it..DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies. The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them. Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing. Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company`s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company`s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company`s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://otcpicknews.com/emailmarketer/link.phpM940&N75&L=7&F=T and FINRA at http://otcpicknews.com/emailmarketer/link.phpM940&N75&L=8&F=T. Disclosure: OTCPicks.com and affiliates have been not been compensated by any of the companies covered in this release.

This entry was posted in OTCPicks Publisher and tagged , , , , , , , , , , . Bookmark the permalink.

Comments are closed.